Answer
Using FEIBA with systemic tranexamic acid or aminocaproic acid carries a potential risk of thromboembolic events; these antifibrinolytics should not be used for approximately 6–12 hours after FEIBA administration.
Sources for this answer
- FEIBA 100 U/ml powder and solvent for solution for infusionTakeda UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 2Document updated
Sources checked